Insider Transactions in Q1 2021 at Kymera Therapeutics, Inc. (KYMR)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2021
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,195
-100.0%
|
$491,700
$60.17 P/Share
|
|
Mar 15
2021
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,195
+50.0%
|
$16,390
$2.08 P/Share
|
|
Mar 15
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,305
-19.5%
|
$618,300
$60.17 P/Share
|
|
Mar 15
2021
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,800
+12.86%
|
$7,800
$1.31 P/Share
|
|
Mar 12
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
229,350
-100.0%
|
$12,843,600
$56.5 P/Share
|
|
Mar 12
2021
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
229,350
-100.0%
|
$12,843,600
$56.5 P/Share
|
|
Mar 11
2021
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,805
-100.0%
|
$108,300
$60.07 P/Share
|
|
Mar 11
2021
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,805
+50.0%
|
$3,610
$2.08 P/Share
|
|
Mar 11
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,695
-9.44%
|
$281,700
$60.05 P/Share
|
|
Mar 11
2021
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+4.24%
|
$2,200
$1.31 P/Share
|
|
Mar 08
2021
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-92.32%
|
$510,000
$51.3 P/Share
|
|
Mar 08
2021
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$20,000
$2.08 P/Share
|
|
Mar 03
2021
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,000
-75.34%
|
$880,000
$44.98 P/Share
|
|
Mar 03
2021
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$40,000
$2.08 P/Share
|
|
Feb 24
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,675
-15.43%
|
$433,750
$50.91 P/Share
|
|
Feb 23
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,285
-25.54%
|
$944,965
$49.65 P/Share
|
|
Feb 22
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,104
-10.76%
|
$473,408
$52.63 P/Share
|
|
Feb 19
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,887
-9.51%
|
$488,785
$55.09 P/Share
|
|
Feb 18
2021
|
Atlas Venture Fund X, L.P. |
SELL
Other acquisition or disposition
|
Direct |
1,063,351
-13.38%
|
-
|
|
Feb 18
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,499
-6.5%
|
$357,445
$55.94 P/Share
|
|
Feb 17
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,550
-7.02%
|
$437,900
$58.39 P/Share
|